Welcome to our dedicated page for Danaher news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher stock.
Danaher Corporation reports developments tied to its global life sciences and diagnostics businesses, where its companies provide scientific technologies, clinical diagnostic systems and tools used in discovery, diagnosis and therapy development. Recurring updates include earnings calls, dividend actions, investor conference appearances and product or regulatory milestones from operating businesses such as Beckman Coulter Diagnostics.
Company news also covers diagnostic assays, immunoassay analyzer platforms, clinical-laboratory workflows and the Danaher Business System, which the company uses as an operating framework across its businesses. Additional recurring themes include shareholder voting matters, governance updates and capital-structure disclosures.
Henry Schein (Nasdaq: HSIC) elected William K. “Dan” Daniel as Independent Chairman of the Board, effective May 21, 2026. He succeeds Stanley M. Bergman, who retired from the Board after 44 years and was named Chairman Emeritus.
Daniel brings decades of healthcare and industrial leadership, including 14 years as Executive Vice President at Danaher (NYSE: DHR) overseeing multiple segments, such as its dental portfolio, and board service at Envista (NYSE: NVST). Company leadership highlighted his understanding of Henry Schein’s business and markets as important for advancing its long-term strategy and integrated healthcare solutions platform.
Danaher (NYSE: DHR) announced that President and CEO Rainer M. Blair will present at the Bank of America Securities Health Care Conference in Las Vegas on May 13, 2026 at 11:20 a.m. PT. The presentation will be simultaneously webcast on www.danaher.com.
Danaher (NYSE: DHR) announced a regular quarterly cash dividend of $0.40 per share, payable on July 31, 2026 to shareholders of record on June 26, 2026.
The Board of Directors approved the dividend on May 5, 2026.
Masimo (Nasdaq: MASI) shareholders approved the merger agreement with Danaher (NYSE: DHR) at a special meeting held May 1, 2026. Under the agreement, each Masimo share will be converted into $180.00 in cash at closing. The merger remains subject to customary closing conditions, including required regulatory approvals and clearances. Masimo expects the transaction to close in 2026 and to operate as an independent operating company within Danaher’s Diagnostics segment.
CD&R announced that Jim Lico, former President and CEO of Fortive, has been engaged as an Operating Advisor to CD&R funds effective April 28, 2026. Lico will support the Firm’s industrials team on sourcing investments and advising portfolio industrial businesses. He led Fortive from 2016–2025, helping grow market capitalization from $16B to $25B and delivering annual revenues above $6B. Lico serves on the boards of DuPont (DD) and PTC and brings nearly three decades of industrial and operational experience.
Danaher (NYSE: DHR) priced a €3.0 billion senior notes offering with four tranches due 2028, 2030, 2034 and 2038.
Net proceeds are estimated at approximately €2.98 billion, intended primarily to pay a portion of the cash consideration and certain costs for the acquisition of Masimo, with closing expected April 29, 2026.
Danaher (NYSE: DHR) reported Q1 2026 results: net earnings $1.0B and GAAP EPS $1.45. Revenues rose 3.5% to $6.0B; non-GAAP adjusted diluted EPS grew 9.5% to $2.06. Operating cash flow was $1.3B; non-GAAP free cash flow $1.1B. The company announced its intention to acquire Masimo and raised full‑year adjusted EPS guidance to $8.35–$8.55. Management expects 2026 non‑GAAP core revenue growth of 3%–6% and reiterated a Q2 low‑single digit revenue outlook.
Beckman Coulter Diagnostics (NYSE:DHR) received CE 2797 mark under IVDR on April 13, 2026 for the Access MeMed BV assay, enabling bacterial vs. viral differentiation in about 20 minutes on DxI 9000 and Access 2 analyzers across Europe.
The assay is supported by clinical studies and real‑world data showing up to 99% NPV and clinician impact in 82–87% of cases; independent modeling estimates up to €80 million in avoidable European healthcare costs through fewer unnecessary admissions and testing.
Danaher (NYSE: DHR) will host its First Quarter 2026 earnings conference call on Tuesday, April 21, 2026 at 8:00 a.m. ET.
The one-hour webcast will include discussion of financial results and outlook, a slide presentation, and a replay; earnings materials will be posted to the Investors section beginning at 6:00 a.m. ET on the call date.
Danaher (NYSE: DHR) announced a regular quarterly cash dividend of $0.40 per share, payable April 24, 2026, to shareholders of record on March 27, 2026.
The Board of Directors approved the dividend on February 24, 2026; the payment and record dates are specified for shareholder planning.